Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma

Imagem de Miniatura
Arquivos
art_PASSEROTTI_Testing_for_urinary_hyaluronate_improves_detection_and_grading_2011.PDF (595.32 KB)
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
BOMFIM, Alexandre C.
MARTINS, Joao Roberto M.
SAMPAIO, Lucia O.
ORTIZ, Valdemar
DIETRICH, Carl P.
NADER, Helena B.
Citação
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, v.29, n.6, p.710-715, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: The purpose of this study is to establish a method for the diagnosis and grading of transitional cell carcinoma (TCC), which is responsible for 90% of bladder tumors, using a recently developed ultrasensitive assay for the measurement of hyaluronan (HA). Materials and methods: Urine samples were collected prior to surgery (cystoscopy, transurethral resection for bladder cancer (TURBT), and cystectomy) in 350 patients. After the procedure, pathologic examination revealed that 160 patients had TCC. HA was measured directly in the urine by a noncompetitive enzyme-linked immunosorbent assay (ELISA)-like fluorometric assay. Using the receiver operator characteristic curve (ROC), t-test, Dunn test, Kruskal-Wallis test, and Mann-Whitney test, we evaluated the differences between groups (those with TCC vs. those without TCC). Results: By analyzing the ROC curve, we chose a urinary HA cutoff value of 13.0 mu g/l for indicating risk of TCC. Using the value this of 13.0 mu g/l, we found that this test had an overall sensitivity of 82.3% and an overall specificity of 81.2%. The positive predictive value of this assay was 78.9%, the negative predictive negative value was 84.2%, and the predictive accuracy was 81.7%. Logistic regression analysis revealed that every 1 mu g/l increase in HA increased a patient's likelihood of having TCC by 3.9%. The sensitivity of this test to detect superficial tumors was 76.6%, whereas its sensitivity for detecting invasive tumors was 94.6%. The urinary HA excretion of patients with TCC, classified according to the TNM staging system and the World Health Organization (WHO) grading system, were compared, and a significant difference was observed between the HA levels of patients with superficial tumors compared with invasive tumors (P = 0.005) as well as between patients with low- vs. high-grade carcinomas (P < 0.001). Patients with urinary HA levels >35 mu g/l had a 4.63 times increased risk of having an aggressive, invasive, high grade tumor (P = 0.005). Conclusions: Our results support the postulate that urinary HA may be used as a tumor marker to aid in the diagnosis and grading of TCC. Additionally, more invasive tumors produce and release more HA in urine than superficial tumors, thus higher HA levels indicate more aggressive disease.
Palavras-chave
Urinary hyaluronan, Tumor marker, Transitional cell carcinoma, Human bladder neoplasms
URI
https://observatorio.fm.usp.br/handle/OPI/22501
Referências
  1. ALTHAUSEN AF, 1976, J UROLOGY, V116, P575
  2. LUTZEYER W, 1982, J UROLOGY, V127, P250
  3. Martins JRM, 2003, ANAL BIOCHEM, V319, P65, DOI 10.1016/S0003-2697(03)00251-3
  4. Lokeshwar VB, 2000, J UROLOGY, V163, P348, DOI 10.1016/S0022-5347(05)68050-0
  5. BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7
  6. HENEY NM, 1983, J UROLOGY, V130, P1083
  7. Lokeshwar VB, 2000, UROL CLIN N AM, V27, P53, DOI 10.1016/S0094-0143(05)70234-2
  8. Passerotti CC, 2006, EUR UROL, V49, P71, DOI 10.1016/j.eururo.2005.09.015
  9. Lotan Y, 2003, UROLOGY, V61, P109, DOI 10.1016/S0090-4295(02)02136-2
  10. HASCALL VC, 1974, J BIOL CHEM, V249, P4232
  11. Simon MA, 2003, CRIT REV ONCOL HEMAT, V47, P91, DOI 10.1016/S1040-8428(03)00074-X
  12. DELPECH B, 1985, ANAL BIOCHEM, V149, P555, DOI 10.1016/0003-2697(85)90613-X
  13. Lokeshwar VB, 1997, CANCER RES, V57, P773
  14. LAURENT TC, 1992, FASEB J, V6, P2397
  15. HALLEN A, 1972, J CHROMATOGR, V71, P83, DOI 10.1016/S0021-9673(01)85691-0
  16. Hanke M, 2010, UROL ONCOL-SEMIN ORI, V28, P655, DOI 10.1016/j.urolonc.2009.01.027
  17. HARDINGH.TE, 1972, BIOCHIM BIOPHYS ACTA, V279, P401, DOI 10.1016/0304-4165(72)90160-2
  18. HENEY NM, 1983, J UROLOGY, V130, P895
  19. Jemal A, 2009, CA CANC J CLIN, V59, P1
  20. KONGTAWELERT P, 1989, ANAL BIOCHEM, V178, P367, DOI 10.1016/0003-2697(89)90654-4
  21. KONGTAWELERT P, 1990, ANAL BIOCHEM, V185, P313, DOI 10.1016/0003-2697(90)90300-X
  22. LAURENT UBG, 1980, ANAL BIOCHEM, V109, P386, DOI 10.1016/0003-2697(80)90665-X
  23. LINKER A, 1960, J BIOL CHEM, V235, P924
  24. Martins JRM, 2004, CLIN ENDOCRINOL, V60, P726, DOI 10.1111/j.1365-2265.2004.02044.x
  25. RO JY, 1992, UROL CLIN N AM, V19, P435
  26. Rossler A, 1998, CLIN CHIM ACTA, V270, P101, DOI 10.1016/S0009-8981(97)00211-8
  27. Song Ji-wen, 2009, Zhonghua Zhongliu Zazhi, V31, P274, DOI 10.3760/cma.j.issn.0253-3766.2009.04.010
  28. Sozen S, 2003, BJU INT, V92, P531, DOI 10.1046/j.1464-410X.2003.04427.x

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/55